title: Approvals in 2016: the march of the checkpoint inhibitors.
authors.affiliation: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10,903 New Hampshire Avenue, Silver Spring, Maryland 20903, USA.
authors.forename: Gideon M
authors.initials: GM
authors.lastname: Blumenthal
authors.affiliation: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10,903 New Hampshire Avenue, Silver Spring, Maryland 20903, USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Pazdur
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D017277:Drug Approval / Q000706:statistics & numerical data*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; C423236:CD274 protein, human